OFFICIAL PUBLICATION OF

by its subsidiary APPco

Research Roundup

Debbie Rigby 02/02/2021

Debbie Rigby rounds up the latest in research news Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes A large systematic review and network meta-analysis of 764 randomised controlled trials has concluded that SGLT-2 inhibitors and GLP-1 receptor agonists reduced cardiovascular and renal outcomes in patients with type 2

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘We have got to make it through the hard stuff first’

Absolutely. But getting people to change their diet and lifestyle is very difficult. So instead we do what we do,…

Leopold Hamulczyk

‘We need more pharmacists’

Unfortunately, enrollment into pharmacy school is dwindling in Australia as nobody in their right mind would do a degree just…

Morbidly Obese John

No products available

Methinks those numbers are somewhat exaggerated. 4 to 7 hours per week dealing with the issue?

Leopold Hamulczyk

Medics to ‘fight’ Doctor of Pharmacy title

Don't forget AMA represnets about 12% of GPs

Greg Cadorin

Research Roundup

Previous The debate goes on

Next Time running out on APP2021 Super Early Bird savings

Ceramides: what are they and why are they important?

In the beginning

The signs of ageing

Hyperpigmentation

MENU

Previous The debate goes on

Next Time running out on APP2021 Super Early Bird savings

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.